We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Lectin with Sialic Acid Specificity Blocks Melanoma Metastasis in Mouse Model

By LabMedica International staff writers
Posted on 06 Aug 2012
Print article
A lectin isolated from the seeds of the Maackia amurensis tree blocks the migration of melanoma cells both in culture dishes and in a mouse skin-cancer model.

Maackia amurensis has been used as a medicinal plant for several centuries to treat ailments including cancer in parts of Asia. Modern studies point to a lectin, MASL, with specificity for alpha-2,3-sialic acid residues as being the medically active component. Lectins are plant proteins or glycoproteins that bind with high specificity to sugar moieties such as those found on cell membrane surface glycoproteins.

Investigators at the University of Medicine and Dentistry of New Jersey (Newark, USA) treated melanoma cell cultures with MASL and treated mice with skin cancer with oral doses of MASL over a period of three weeks. The combination of MASL and melanoma was selected for study because prior research had shown that motility of melanoma cells was regulated by the mucin-receptor protein podoplanin (PDPN). PDPN is activated by endogenous ligands to induce tumor cell motility and metastasis. The extracellular domain of PDPN is highly O-glycosylated with alpha-2,3-sialic acid linked to galactose.

Results reported in the July 23, 2012, online edition of the journal PLoS ONE revealed that MASL inhibited melanoma cell growth, migration, and tumorigenesis under the controlled conditions of cell culture. What was more surprising was that the lectin effectively blocked melanoma metastasis in the skin after passing through the digestive tracts of the mice. Of critical importance to future drug development was the finding that MASL caused no notable toxic effects on organ morphology or animal behavior over the three-week period of treatment.

“Cells, even when they are cancerous, tend to stay put,” said senior author Dr. Gary Goldberg, professor of molecular biology at the University of Medicine and Dentistry of New Jersey. “PDPN allows tumor cells to break out of their microenvironment, invade new areas, and metastasize. Our laboratory research shows that MASL not only significantly reduces cell migration it also inhibits cancer cell growth. The absence of any noticeable side effects is not surprising. For centuries, MASL has been taken as a component in medicinal plant extracts used to treat a variety of ailments including cancer. According to standard traditional protocols, these preparations contain very high doses of MASL, yet we cannot find any reports of toxicity from its use.”

Related Links:
University of Medicine and Dentistry of New Jersey



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)

Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.